Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Prefibrotic Primary Myelofibrosis As an Entity Distinct from Other Philadelphia-Chromosome Negative Myeloproliferative Neoplasms - Data from the Austrian Reclassification Project

Georg Jeryczynski, MD, Bettina Gisslinger, Martin Schalling, Maria Theresa Krauth, MD, Leonhard Muellauer, MD, Ana-Iris Schiefer, MD, Christoph Kornauth, MD, Ingrid Simonitsch-Klupp, MD, Jürgen Thiele, MD PhD, Heinz Gisslinger

Blood (2016) 128 (22): 4252.

https://doi.org/10.1182/blood.V128.22.4252.4252

Published: 2016

Journal Articles

In Contemporary Patients with Polycythemia Vera, Rates of Thrombosis and Risk Factors Delineate a New Clinical Epidemiology

Tiziano Barbui, MD, Alessandra Carobbio, MSc, Elisa Rumi, MD, Guido Finazzi, MD, Heinz Gisslinger, MD, Francesco Rodeghiero, Maria Luigia Randi, MD, Alessandro Rambaldi, Bettina Gisslinger, MSc, Lisa Pieri, MD PhD, Irene Bertozzi, Ilaria Carola Casetti, MD, Leonhard Müllauer, MD, Animesh Pardanani, MBBS, PhD, Jürgen Thiele, MD PhD, Francesco Passamonti, MD, Alessandro M. Vannucchi, MD, Ayalew Tefferi, MD

Blood (2014) 124 (21): 1822.

https://doi.org/10.1182/blood.V124.21.1822.1822

Published: 2014

Journal Articles

Effects Of Five-Years Of Ruxolitinib Therapy On Bone Marrow Morphology In Patients With Myelofibrosis and Comparison With Best Available Therapy

Hans Michael Kvasnicka, MD, PhD, Jürgen Thiele, MD, PhD, Carlos E. Bueso-Ramos, MD, PhD, William Sun, PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD, PhD

Blood (2013) 122 (21): 4055.

https://doi.org/10.1182/blood.V122.21.4055.4055

Published: 2013

Journal Articles

Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis

Catriona HM Jamieson, MD, PhD, Robert P Hasserjian, MD, Jason Gotlib, MD, MS, Jorge E. Cortes, MD, Richard M. Stone, MD, Moshe Talpaz, MD, Jürgen Thiele, MD, PhD, Scott J Rodig, MD, PhD, Abhay Patki, PhD MBA, Kaida Wu, PhD, MD, Jingyang Wu, MSc, Olga Pozdnyakova, MD, PhD

Blood (2013) 122 (21): 2823.

https://doi.org/10.1182/blood.V122.21.2823.2823

Published: 2013

Journal Articles

Correlation Of Longitudinal Blood Counts With Thromboembolic Complications In WHO 2008 Defined Prefibrotic Primary Myelofibrosis

Veronika Buxhofer-Ausch, Martin Schalling, Sophie Frantal, Jürgen Thiele, MD, PhD, Leonhard Muellauer, M.D., Hans-Michael Kvasnicka, MD, Bettina Gisslinger, Heinz Gisslinger, MD

Blood (2013) 122 (21): 2834.

https://doi.org/10.1182/blood.V122.21.2834.2834

Published: 2013

Journal Articles

Masked Polycythemia Vera (mPV): Results Of An International Study

Tiziano Barbui, MD, Jürgen Thiele, MD, PhD, Heinz Gisslinger, MD, Guido Finazzi, Alessandra Carobbio, MSc, Elisa Rumi, MD, Maria Luigia Randi, MD, Alessandro M. Vannucchi, MD, Lisa Pieri, MD, PhD, Bettina Gisslinger, Leonhard Muellauer, M.D., Marco Ruggeri, MD, Alessandro Rambaldi, MD, Ayalew Tefferi, MD

Blood (2013) 122 (21): 1581.

https://doi.org/10.1182/blood.V122.21.1581.1581

Published: 2013

NARROW

Prefibrotic Primary Myelofibrosis As an Entity Distinct from Other Philadelphia-Chromosome Negative Myeloproliferative Neoplasms - Data from the Austrian Reclassification Project

In Contemporary Patients with Polycythemia Vera, Rates of Thrombosis and Risk Factors Delineate a New Clinical Epidemiology

Effects Of Five-Years Of Ruxolitinib Therapy On Bone Marrow Morphology In Patients With Myelofibrosis and Comparison With Best Available Therapy

Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis

Correlation Of Longitudinal Blood Counts With Thromboembolic Complications In WHO 2008 Defined Prefibrotic Primary Myelofibrosis

Masked Polycythemia Vera (mPV): Results Of An International Study

Email alerts

ASH Publications

American Society of Hematology

Prefibrotic Primary Myelofibrosis As an Entity Distinct from Other Philadelphia-Chromosome Negative Myeloproliferative Neoplasms - Data from the Austrian Reclassification Project

In Contemporary Patients with Polycythemia Vera, Rates of Thrombosis and Risk Factors Delineate a New Clinical Epidemiology

Effects Of Five-Years Of Ruxolitinib Therapy On Bone Marrow Morphology In Patients With Myelofibrosis and Comparison With Best Available Therapy

Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis

Correlation Of Longitudinal Blood Counts With Thromboembolic Complications In WHO 2008 Defined Prefibrotic Primary Myelofibrosis

Masked Polycythemia Vera (mPV): Results Of An International Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only